Filana Therapeutics, Inc.
FLNA
$1.42
-$0.01-0.70%
NASDAQ
| 03/31/2026 | 12/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | 17.93% | -2.58% | |||
| Gross Profit | -17.93% | 2.58% | |||
| SG&A Expenses | 16.23% | -27.91% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 16.92% | -19.46% | |||
| Operating Income | -16.92% | 19.46% | |||
| Income Before Tax | 17.61% | -16.03% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 17.61% | -16.03% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 17.61% | -16.03% | |||
| EBIT | -16.92% | 19.46% | |||
| EBITDA | -18.94% | 21.69% | |||
| EPS Basic | 0.00% | -16.05% | |||
| Normalized Basic EPS | -- | 20.96% | |||
| EPS Diluted | 0.00% | -16.27% | |||
| Normalized Diluted EPS | -- | 20.96% | |||
| Average Basic Shares Outstanding | -- | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||